Brown Brothers Harriman & Co. Cuts Stake in Kenvue Inc. (NYSE:KVUE)

Brown Brothers Harriman & Co. trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 20.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 317,046 shares of the company’s stock after selling 80,543 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Kenvue were worth $6,769,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Grove Bank & Trust boosted its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue in the 4th quarter worth $29,000. SRS Capital Advisors Inc. raised its position in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after buying an additional 571 shares during the period. Fortitude Family Office LLC boosted its holdings in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on KVUE. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Barclays raised their price target on shares of Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Thursday. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. UBS Group cut their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Finally, Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $24.00.

Kenvue Trading Up 1.0 %

Shares of KVUE opened at $23.74 on Friday. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The stock has a 50-day moving average price of $22.32 and a 200 day moving average price of $22.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $45.36 billion, a P/E ratio of 44.78, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.45%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.